Table 3. Hemodynamics data, exercise capacity, biochemistry and echocardiogram data before and after riociguat treatment.
| Pre-medication (N = 11) | Post-medication (N = 11) | Change | p value | |
| Right heart hemodynamic studies | ||||
| RAP, mmHg | 8 ± 5 | 8 ± 4 | 0.4 ± 2.4 | 1.000 |
| Systolic PAP, mmHg | 73 ± 18 | 68 ± 21 | 5 ± 9 | 0.078 |
| Diastolic PAP, mmHg | 25 ± 6 | 22 ± 6 | 2 ± 5 | 0.164 |
| Mean PAP, mmHg | 41 ± 8 | 38 ± 9 | 4 ± 5 | 0.045 |
| PCWP, mmHg | 13 ± 6 | 13 ± 4 | 0.1 ± 4.1 | 0.942 |
| Cardiac output, liters/min | 3.6 ± 1.4 | 4.2 ± 1.0 | 0.6 ± 0.9 | 0.052 |
| PVR, dyn·s·cm-5 | 787 ± 417 | 478 ± 267 | 268 ± 222 | 0.007 |
| Exercise capacity | ||||
| WHO Fc | 0.004 | |||
| I | 0 | 5 | Improved (9/11) | |
| II | 6 | 5 | Stationary (2/11) | |
| III | 4 | 1 | Worse (0/11) | |
| IV | 1 | 0 | ||
| 6MWD | 375 ± 68 | 388 ± 77 | 21 ± 79 | 0.635 |
| NT-proBNP | ||||
| NT-proBNP, pg/mL | 281 (117-5943) | 226 (48-1276) | 177 (-6.1-3450) | 0.021 |
| Log NT-proBNP | 2.8 ± 0.8 | 2.4 ± 0.7 | 0.4 ± 0.4 | 0.007 |
| Echocardiogram* | ||||
| LVEF, mm | 69 ± 9 | 73 ± 5 | 4 ± 9 | 0.227 |
| LVEDD, mm | 45 ± 6 | 45 ± 6 | 1 ± 2 | 0.074 |
| LA diameter, mm | 36 ± 4 | 39 ± 4 | 2 ± 5 | 0.227 |
| TR grading | 0.480 | |||
| Moderate | 5 | 6 | Improved (3/10) | |
| Moderate to severe | 4 | 4 | Stationary (5/10) | |
| Severe | 1 | 0 | Worse (2/10) | |
| TRPG, mmHg | 78 ± 19 | 74 ± 24 | 4 ± 23 | 0.558 |
* Data was collected from 10 patients.
Data were presented as mean ± standard deviation or median (25th-75th percentile).
LA, left atrium; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; TR, tricuspid regurgitation; TRPG, tricuspid regurgitation peak gradient; WHO Fc, World Health Organization functional class; 6MWD, 6-minute walk distance.